ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
ScreenNC: A Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the SARS-CoV-2 Infection
Sponsor: University of North Carolina, Chapel Hill
A observational or N/A phase clinical study on Asymptomatic Condition and Communicable Disease, this trial is completed. The trial is conducted by University of North Carolina, Chapel Hill and has accumulated 10 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2023 — Jul 2024 [monthly]
Completed
Status: Enrolling By Invitation → Completed
-
Feb 2022 — Feb 2023 [monthly]
Enrolling By Invitation
-
Dec 2021 — Feb 2022 [monthly]
Enrolling By Invitation
▶ Show 5 earlier versions
-
Apr 2021 — Dec 2021 [monthly]
Enrolling By Invitation
-
Jan 2021 — Apr 2021 [monthly]
Enrolling By Invitation
-
Nov 2020 — Jan 2021 [monthly]
Enrolling By Invitation
-
Jul 2020 — Nov 2020 [monthly]
Enrolling By Invitation
-
May 2020 — Jul 2020 [monthly]
Enrolling By Invitation
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of North Carolina, Chapel Hill
For direct contact, visit the study record on ClinicalTrials.gov .